Fast Company has published a new analysis titled "Why corporate innovation keeps failing," returning one of the most persistent questions in R&D management to the front of the trade debate: why do well-funded corporate innovation programs so rarely produce durable results?

The article's headline is itself a verdict. It does not ask whether corporate innovation fails; it asserts that failure is recurring and, implicitly, structural. For R&D managers and portfolio leads, that framing will feel familiar. Corporate innovation units, incubators and digital labs have multiplied across large firms over the past two decades, and a steady stream of shutdowns, quiet downsizings and rebrandings has followed them.

The headline feeds a long-running argument in the R&D management literature. That argument centers on a core tension: large companies optimize for operational efficiency and predictable returns, while genuinely new research and venture work demands tolerance for ambiguity, long horizons and failure rates that clash with quarterly reporting cycles.

What does the headline claim, and what can it support?

Hypothesis Wire has not yet reviewed the full text of the Fast Company piece beyond its title. We treat the headline as data to interrogate, not a conclusion to repeat. A headline asserting systematic failure can mean several distinct things:

• Innovation units are closed before their work matures.
• Projects pass stage gates but never reach commercial scale.
• Successful spinouts leave the parent company rather than transform it.
• Metrics reward activity — launches, pilots, partnerships — rather than measured business impact.

Each of those failure modes implies a different management fix, from portfolio design to incentive reform. Readers should watch which mechanism the article actually documents.

Why this matters for R&D budget decisions

For R&D managers, the recurring-failure thesis has direct budget consequences. If corporate innovation programs fail for structural reasons rather than execution reasons, then increasing funding to an unchanged structure buys more of the same outcome. The relevant questions become:

• Does the innovation unit control a real P&L, or does it depend on discretionary corporate funding renewed annually?
• Are project kill criteria defined in advance, with measured milestones, or do projects persist on sponsorship alone?
• Is there a tracked path from pilot to integration within a business unit, with a named owner on the receiving side?

These are the questions any serious post-mortem of failed corporate innovation programs tends to surface, and they are the questions Fast Company's analysis will be judged against.

Measured results versus claims

Vendor and consultancy claims about innovation-program success rates deserve the same scrutiny the article applies to corporations themselves. When a consultancy reports that most innovation initiatives miss their targets, check who funded the survey, how "innovation initiative" was defined, and the sample size. Headline failure statistics that circulate in this field often blend survey self-reports with vendor marketing.

The stronger evidence base sits in longitudinal case work: documented programs with start dates, funding levels, and closure outcomes. Fast Company's piece will carry more weight if it anchors its thesis in named companies, dated program closures and quantified outcomes rather than generalized diagnosis.

What should R&D leaders watch next?

If the article's argument is structural — that corporate structures select against disruptive innovation by design — the practical response is not to abolish innovation units but to change their contract with the core business: explicit integration paths, protected multi-year funding, and failure metrics agreed before launch rather than defended after it.

Fast Company's analysis, once read in full, will either document those mechanisms or fall back on the familiar cultural critique. R&D managers should read it with the first question in mind: does the evidence separate structural failure from ordinary execution failure, and does it propose a testable fix? Expect follow-on commentary from the R&D management community as the piece circulates.